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Primary vitreo-retinal lymphoma (PVRL) is often associated with primary central nervous system lymphoma (PCNSL), and is a rare high-grade diffuse large cell B-cell lymphoma (DLBCL) occurring within the vitreous and/or retina  ADDIN EN.CITE 1-3.
Overlapping clinical signs observed in PVRL and chronic vitritis often mislead ophthalmologists to diagnose the latter rather than PVRL. The pathological diagnosis of PVRL is usually established by morphological examination of vitreous biopsies and/or subretinal aspirates, followed by immunoprofiling and genetic analyses  ADDIN EN.CITE 1,4. Despite this work-up, the false negative diagnostic rate is still estimated to be up to 30% in PVRL 2, particularly in paucicellular specimens containing only necrotic tumor cells. Therefore, novel non-cellular biomarkers within the sample supernatant are required in the diagnostic repertoire of PVRL.
Previously, we have demonstrated an up-regulation of certain microRNAs - miR-92, miR-19b, and miR-21 - in the central spinal fluid (CSF) of PCNSL patients, compared to CSF of patients with other neoplastic and inflammatory CNS diseases  ADDIN EN.CITE 5,6. Since there are distinct similarities between PVRL and PCNSL 7, we hypothesized, that the same microRNAs could be up-regulated in PVRL vitreous specimens compared to those with vitritis.


Ruhr-University ethic committee approval (register no. 4704-13, Bochum, Germany) was obtained for the vitreous sample collection.
All vitreous samples were collected prospectively by pars-plana vitrectomy before initiation of any chemotherapy, and following discontinuation of cortisone therapy. Vitreous samples from 10 PVRL patients were included. In all PVRL samples, the diagnosis of DLBCL was established following standard practice in the ocular oncology reference centers. IgH-PCR was also performed in 3 cases. The PVRL was newly diagnosed in all patients. As controls we used 40 vitreous samples from histopathologically confirmed vitritis patients, and 7 vitreous samples from non-inflammatory macular pucker patients. The clinical data were recorded for all patients and summarized in Table 1a. Vitreous samples were centrifuged within 30 min (500g, 10 min, room temperature). The supernatants were stored at -80°C for further processing and miRNA analysis.
Total RNA was extracted using the mirVana RNA isolation kit (Ambion®, ThermoFisher Scientific, Waltham, MA, USA), according to manufacturer’s instructions. Briefly, 0.4 mL of vitreous was diluted with mirVana PARIS 2X denaturing solution. Equal volumes of acid/phenol/chloroform were added to each aliquot, and centrifuged. Following this, glycogen was added to the aqueous phases, which were subsequently mixed with 1.25 volumes of 100% ethanol. After passage through a mirVana PARIS column, several washing steps were carried out. 
TaqMan miRNA assays (Applied Biosystems) to quantify miRNA levels were applied as has previously been published  ADDIN EN.CITE 5,6. The synthetic miRNAs, cel-54 and miR-769, not present in human vitreous, were chosen as reference molecules for normalization. The amount of miR-92, miR-19b and miR-21 was normalized relative to the mean amount of cel-miR-54 and miR-769 (Ct = (Ct(cel-miR-54) + Ct(miR-769)) / 2 – Ct(miR-92 or miR-19b or miR-21 )).
Statistical analyses were performed using SPSS (v.20; SPSS) and GraphPad Prism (v.5.0). Group-wise comparisons of distributions of clinical and biologic data were performed, applying 2-tailed Mann–Whitney U tests and Kruskal– Wallis tests with Dunn multiple comparisons.


Distinguishing PVRL and vitritis remains a major clinical challenge, even in some cases following extensive pathological evaluation of vitreous biopsies using a variety of diagnostic techniques. In this study, we assessed whether miR-92, miR-19b, and miR-21 levels in the non-cellular component (i.e. the supernatant) of centrifuged vitreous biopsies could be used to differentiate patients with PVRL (n=10) from macular pucker patients without any inflammation (n=7). All three miRNA candidates were significantly up-regulated in vitreous of PVRL patients (Tab. 1b; Fig.1a-c). Further, when comparing miR-92, miR-19b and miR-21 levels in the vitreous of PVRL patients with those from vitritis patients (n=40), we found miR-92, miR-19b, and miR-21 levels to be significantly up-regulated in PVRL patients (Tab.1b; Fig. 1a-c).
To test all three miRNA candidates for their ability to discriminate between PVRL and vitritis, area-under-the curve (AUC) calculations were performed. MiR-92 revealed an AUC of 0.9725 (Fig.1d). Corresponding to this analysis, cut-off vitreous relative quantification value (REL) with the highest accuracy for miR-92 was determined as follows: REL -10.82 with 100 % sensitivity and 90 % specificity. MiR-19b and miR-21 demonstrated AUC of 0,94 and 0,8125 by comparison of PVRL with vitritis, respectively (Fig.1e and f).
Various methods are used in PVRL diagnostics: cytological and immunocytochemical analyses are standard procedures 1. Diagnostic rates of PVRL using cytological analysis only are estimated to be between 45-60%  ADDIN EN.CITE 8-10. Additional immunophenotyping for B-cell markers (e.g. CD20, PAX5, and CD79a) has improved this rate, with a sensitivity of 80% and a specificity of 100%  ADDIN EN.CITE 1,8,11. Some centers also use evaluation of interleukins (IL) 6 and 10 ratios in the aqueous and vitreous, as an adjunctive diagnostic tool in PVRL  ADDIN EN.CITE 12-14. Other centers prefer clonality analysis (i.e. IgH-PCR or IgL-PCR) when there is sufficient residual sample. The sensitivity for PCR-based clonality does vary between 65% and 95%, as PVRL cells are highly mutated in the IgH-variable region, and they can be masked by a dense reactive inflammatory infiltrate, leading to false negatives  ADDIN EN.CITE 1,4,10,12,15-18. 
More recent tests have developed targeting genetic alterations in VRL, requiring smaller DNA concentrations. Bonzheim et al. demonstrated the presence of MYD88 mutation L265P in a retrospective analysis in 71% of PVRL  ADDIN EN.CITE 18, and demonstrated an increase in PVRL diagnosis from 62% to 90% when MYD88 mutation analysis was included in the sample work-up  ADDIN EN.CITE 18. Further, next generations analysis identified MYD88 mutation CDK2NA in PVRL as a new diagnostic target  ADDIN EN.CITE 19.  
In parallel to the above, evaluations of vitreous samples for miRNA levels have been undertaken. Tuo et al. investigated miRNA levels in 3 PVRL samples and compared these to 3 vitreous specimens with uveitis, using a real-time PCR-based miRNA panel  ADDIN EN.CITE 20. Of the 168 miRNAs analyzed in the panel, 3 miRNAs miR-484, -197 and -132 were up-regulated in PVRL, and 3 miRNAs miRNA-155, -200c, -22* were up-regulated in the ocular fluid  ADDIN EN.CITE 20. After individual miRNA real-time PCR in all specimens (PVRL n=17, uveitis n=12) only miRNA-155 was approximately 2-fold up-regulated in uveitis specimens  ADDIN EN.CITE 20. Interestingly, in Tuo’s report, miR-21, miR-19b, and miR-92 were not described to be differentially expressed  ADDIN EN.CITE 20. The data of Tuo et al. and of our study are not comparable, due to the differences in PVRL diagnosis analysis and to sample preparation, and due to the usage of different assays. 
To our knowledge, this is the first observation of deregulated miR-21, miR-19b and miR-92 expression in vitreous samples from PVRL patients. The relatively small number in the examined cohort is due to the rarity of this disease, and a larger validation study is required. However, the results of this study are of clear importance, due to the high level of discrimination, when miRNA expression in PVRL is compared to that of vitritis and macular pucker. We propose that miRNA analysis could represent a new adjunctive test in the PVRL diagnostic repertoire, providing supportive evidence to the morphological, immunocytological and genetic evaluations. An advantage is that the miRNA would utilize the supernatant of the centrifuged vitreous sample, leaving the cellular component for profiling and DNA-based tests. We suggest that time delays to definitive diagnosis of this high-grade malignancy could be reduced. Nevertheless, a larger prospective study is required to validate our results.
The miRNA candidates analyzed here have also been established for disease course monitoring in PCNSL patients  ADDIN EN.CITE 5,6. To date, disease course monitoring is difficult in PVRL, although IL6:IL10 aqueous levels are used in some centers. Because of the small fluid volumes required, targeted miRNA analysis should be considered in PVRL diagnostics and monitoring.
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a) Biodata PVRL patients
Biodata of all PVRL patients (Bochum/Germany: 5 PVRL specimens, Münster/Germany: 4 PVRL specimens, Mulhouse/France: 1 PVRL specimens) include age, gender, presence/absence of PCNSL, HIV status, biopsy method, previous cortisone therapy, and relevant clinical signs. All PVRL cases were diagnosed on the basis of morphology and immunoprofiling in the ocular oncology reference centers in Liverpool/United Kingdom, Lübeck/Germany and Mulhouse/France. For three specimens, additional IgH PCR was performed. Abbreviations: PCNSL Primary central nervous system lymphoma; GCs Glucocorticoids; top. Topical; VTX vitrectomy; IH immunhistology; AC anterior chamber; CME cystoid macular edema; FLA fluorescein angiography; OCT optical coherence topography

b) Relative miR-92, miR-19b and miR-21 expression in vitreous of patients with PVRL versus patients with vitritis and patients with macular pucker
1 Data are means of relative quantification values (REL, groupwise); 2 standard deviation; 3 The p-value is for comparison of expression levels of miR-92, miR-19b and miR-21 among PVRL patients and vitritis patients was calculated using the Mann-Whitney U-Test; 4 The p-value is for comparison of expression levels of miR-92, miR-19b and miR-21 among PVRL patients and macular pucker patients was calculated using the Mann-Whitney U-Test.

Fig.1: 
a-c) Scatterplots of expression levels
Scatterplots of expression levels of miR-92 (a), miR-19b (b), and miR-21 (c) in vitreous samples from patients with PVRL (n=10) compared with subgroups of patients with vitritis (n=40), and non-inflammatory macular pucker patients (n=10). The black horizontal lines represent median REL values. Groupwise P values are indicated as determined in Kruskal-Wallis tests with Dunn multiple comparisons (*P<0.05).

d-e) Receiver-operating characteristics curve analyses
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